

Smruthi Vijayaraghavan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6286490/publications.pdf>

Version: 2024-02-01

18
papers

863
citations

933447

10
h-index

1281871

11
g-index

18
all docs

18
docs citations

18
times ranked

1938
citing authors

#	ARTICLE	IF	CITATIONS
1	Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trophocytosis. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2044-2056.	4.1	87
2	Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3996-4013.	7.0	77
3	Abstract 323: Combined inhibition of STAT-3 & DNA repair in palbociclib resistant breast cancer. , 2019, , .		0
4	Abstract 4818: Fc-mediated mechanism of action for the novel EGFR-cMET bispecific antibody (JNJ-61186372) in non-small cell lung cancer. , 2019, , .		0
5	Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 742-757.	0.9	98
6	Molecular genetics and cellular events of K-Ras-driven tumorigenesis. <i>Oncogene</i> , 2018, 37, 839-846.	5.9	69
7	Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. <i>Targeted Oncology</i> , 2018, 13, 21-38.	3.6	78
8	Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. <i>Clinical Cancer Research</i> , 2018, 24, 6594-6610.	7.0	70
9	CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1751-1764.	4.1	39
10	CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. <i>Nature Communications</i> , 2017, 8, 15916.	12.8	214
11	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. <i>Molecular Cancer Research</i> , 2017, 15, 45-58.	3.4	73
12	Abstract 2060: Characterizing acquired resistance to palbociclib in breast cancer. <i>Cancer Research</i> , 2017, 77, 2060-2060.	0.9	3
13	Abstract P5-04-03: Palbociclib synergizes with autophagy inhibitors to induce senescence in breast cancer. , 2017, , .		0
14	Abstract 2338: CDK4/6 and autophagy inhibitors synergize to induce senescence in cancers with an intact G1/S checkpoint. , 2017, , .		0
15	Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 593-607.	4.1	54
16	Abstract 2989: An Intact G1/S checkpoint determines response to CDK4/6 inhibitor in breast cancer. , 2016, , .		0
17	Abstract 1783: Pharmacological inhibition of CDK4/6 induces G1 arrest, autophagy and senescence in ER+ breast cancer. , 2015, , .		1
18	Abstract P5-08-02: Inhibition of CDK4/6 induces senescence and autophagy in ER positive breast cancers. , 2015, , .		0